Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14030
Abstract: Alzheimer's disease (AD) is associated with neurodegenerative changes resulting clinically in progressive cognitive and functional deficits. The only therapies are the cholinesterase inhibitors donepezil, galantamine and rivastigmine and the N‐methyl‐D‐aspartate‐receptor antagonist memantine. Donepezil acts primarily… read more here.
Keywords: donepezil; beyond symptomatic; alzheimer disease; treatment ... See more keywords